SVB Securities analyst Thomas Smith raised the firm’s price target on Pliant Therapeutics to $45 from $33 to reflect better-than-expected 320mg dose cohort results of bexotegrast in the Phase 2a INTEGRIS-IPF study that reinforce confidence that bexo will compete for a best-in-class profile in IPF. The firm has an Outperform rating on the shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PLRX:
- Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
- Pliant Therapeutics price target raised to $55 from $36 at Citi
- Here’s Why Pliant (NASDAQ:PLRX) Stock Is Trending Higher
- Pliant Therapeutics Announces Proposed Public Offering of Common Stock
- Pliant Therapeutics announces $175M common stock offering
